Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.

Kwon JH, Lee N, Park JY, Yu YS, Kim JP, Shin JH, Kim DS, Joh JW, Kim DS, Choi KY, Kang KJ, Kim G, Moon YH, Wang HJ.

PLoS One. 2013 Jun 13;8(6):e64260. doi: 10.1371/journal.pone.0064260. Print 2013.

2.

Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.

Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.

Gastroenterology. 2017 Jun;152(8):2022-2036. doi: 10.1053/j.gastro.2017.02.039. Epub 2017 Mar 8.

PMID:
28284560
3.

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.

Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M.

Hepatology. 2013 Apr;57(4):1407-15. doi: 10.1002/hep.25956. Epub 2013 Feb 11.

PMID:
22890726
4.

Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.

Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, Ao JY, Li JQ, Wang L, Wu WZ, Tang ZY.

PLoS One. 2013 May 31;8(5):e65023. doi: 10.1371/journal.pone.0065023. Print 2013.

5.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.

PMID:
23601249
6.

Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.

Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK.

Hepatology. 2015 Aug;62(2):534-45. doi: 10.1002/hep.27859. Epub 2015 Jun 3.

PMID:
25902734
7.

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.

Xu YY, Chen L, Wang GL, Zhou JM, Zhang YX, Wei YZ, Zhu YY, Qin J.

BMC Cancer. 2013 Nov 6;13:527. doi: 10.1186/1471-2407-13-527.

8.

Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.

Zhai JM, Yin XY, Lai YR, Hou X, Cai JP, Hao XY, Liang LJ, Zhang LJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1255-64. doi: 10.1007/s00280-013-2120-2. Epub 2013 Feb 23.

PMID:
23435877
9.

MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.

Chen Y, Feng F, Gao X, Wang C, Sun H, Zhang C, Zeng Z, Lu Y, An L, Qu J, Wang F, Yang Y.

Curr Cancer Drug Targets. 2015;15(3):176-87.

PMID:
25714700
10.

RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.

Shi JH, Liu SZ, Wierød L, Scholz H, Anmarkrud JA, Huitfeldt HS, Zhang SJ, Line PD.

J Surg Oncol. 2013 Mar;107(4):393-401. doi: 10.1002/jso.23224. Epub 2012 Aug 23.

PMID:
22927239
11.

Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.

Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X, Feng M.

J Surg Oncol. 2013 Mar;107(4):422-7. doi: 10.1002/jso.23227. Epub 2012 Jul 25.

PMID:
22833259
12.

Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.

Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S, De Petro G.

Mol Cancer. 2013 Dec 13;12:162. doi: 10.1186/1476-4598-12-162.

13.

Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Gish RG, Finn RS, Marrero JA.

Clin Adv Hematol Oncol. 2013 Apr;11 Suppl 5:1-22; quiz 2 p following p22.

PMID:
23881427
14.

Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.

Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G.

PLoS One. 2013 Jun 12;8(6):e65569. doi: 10.1371/journal.pone.0065569. Print 2013.

15.

Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines.

Nam SW, Park KC, Choi HS, Lee B, Kim SW.

J Gastroenterol Hepatol. 2014 Mar;29(3):633-9.

PMID:
24716227
16.

Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.

Godin C, Dupont S, Ezzoukhry Z, Louandre C, Chatelain D, Henaut L, Sabbagh C, Regimbeau JM, Maziere JC, Barbare JC, Chauffert B, Galmiche A.

Anticancer Res. 2013 Apr;33(4):1415-20.

PMID:
23564781
17.

Network features suggest new hepatocellular carcinoma treatment strategies.

Lavi O, Skinner J, Gottesman MM.

BMC Syst Biol. 2014 Jul 29;8:88. doi: 10.1186/s12918-014-0088-0.

18.

Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.

Weintraub JL, Salem R.

J Vasc Interv Radiol. 2013 Aug;24(8):1123-34. doi: 10.1016/j.jvir.2013.01.494. Epub 2013 Apr 4. Review.

PMID:
23562168
19.

Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.

Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, Wang L, Song TQ, Li Q, Tang ZY.

Gastroenterology. 2012 Dec;143(6):1641-1649.e5. doi: 10.1053/j.gastro.2012.08.032. Epub 2012 Aug 23.

PMID:
22922424
20.

Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.

Fransvea E, Angelotti U, Antonaci S, Giannelli G.

Hepatology. 2008 May;47(5):1557-66. doi: 10.1002/hep.22201.

PMID:
18318443

Supplemental Content

Support Center